We screened out ASH1L, an H3K4 methyltransferase with higher expression levels in both hepatoma cells and activated HSCs, to avoid generating distinct effects when epigenetically targeting these two cell types. The gene discussed is ASH1L; the disease is hepatocellular carcinoma.